{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T11:54:46Z","timestamp":1775735686864,"version":"3.50.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"VLAIO \u2013 Translational Intestinal Models"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Syst Biol Appl"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cyclooxygenase (COX) inhibitors (COXIBs) have shown preventive and therapeutic potential for colorectal cancer (CRC). In addition to inhibiting COX, approved COXIBs also target COX-independent pathways, including NF-\u03baB and AKT. We evaluated how inhibition of various COXIB targets affects cell proliferation and apoptosis using a Boolean model incorporating the effect of several genetic mutations linked to CRC. The mutations activate two positive feedback loops and cause increased cell proliferation and survival. When simulating loss of function of APC, proliferation and apoptosis can be restored to healthy rates by inhibiting COX2. In simulations reflecting other genetic mutations, none of the investigated targets restore apoptosis and proliferation is reduced by inhibiting AKT or NF-\u03baB, but not by any of the other COX targets tested. These results show that the off-target effects of COXIBs are crucial for their efficacy in the treatment of sporadic CRC.<\/jats:p>","DOI":"10.1038\/s41540-025-00622-x","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:18:35Z","timestamp":1772209115000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Network modeling of sporadic colorectal cancer reveals the importance of off-target effects of Cyclooxygenase inhibitors"],"prefix":"10.1038","volume":"12","author":[{"given":"Anthony R.","family":"Gebhart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manon M. M.","family":"Berns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Snoeys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen","family":"Elassaiss-Schaap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth C. M.","family":"de Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"622_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"622_CR2","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jama.2021.0106","volume":"325","author":"LH Biller","year":"2021","unstructured":"Biller, L. H. & Schrag, D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 325, 669\u2013685 (2021).","journal-title":"JAMA."},{"key":"622_CR3","doi-asserted-by":"crossref","unstructured":"Burgos-Molina, A. M., T\u00e9llez Santana, T., Redondo, M. & Bravo Romero, M. J. The crucial role of inflammation and the immune system in colorectal cancer carcinogenesis: a comprehensive perspective. Int. J. Mol. Sci. 25 (2024).","DOI":"10.3390\/ijms25116188"},{"key":"622_CR4","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1053\/j.gastro.2021.09.059","volume":"161","author":"D Wang","year":"2021","unstructured":"Wang, D., Cabalag, C. S., Clemons, N. J. & DuBois, R. N. Cyclooxygenases and prostaglandins in tumor immunology and microenvironment of gastrointestinal cancer. Gastroenterology 161, 1813\u20131829 (2021).","journal-title":"Gastroenterology"},{"key":"622_CR5","first-page":"3387","volume":"59","author":"BS Reddy","year":"1999","unstructured":"Reddy, B. S. et al. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. Cancer Res. 59, 3387\u20133391 (1999).","journal-title":"Cancer Res."},{"key":"622_CR6","first-page":"1464","volume":"55","author":"CV Rao","year":"1995","unstructured":"Rao, C. V. et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res. 55, 1464\u20131472 (1995).","journal-title":"Cancer Res."},{"key":"622_CR7","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1158\/1940-6207.CAPR-17-0038","volume":"10","author":"S Chandra","year":"2017","unstructured":"Chandra, S., Nymeyer, A. C., Rice, P. F., Gerner, E. W. & Barton, J. K. Intermittent dosing with sulindac provides effective colorectal cancer chemoprevention in the azoxymethane-treated mouse model. Cancer Prev. Res (Philos.) 10, 459\u2013466 (2017).","journal-title":"Cancer Prev. Res (Philos.)"},{"key":"622_CR8","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/j.1349-7006.2001.tb01139.x","volume":"92","author":"Y Yamada","year":"2001","unstructured":"Yamada, Y. et al. Suppression of occurrence and advancement of beta-catenin-accumulated crypts, possible premalignant lesions of colon cancer, by selective cyclooxygenase-2 inhibitor, celecoxib. Jpn. J. Cancer Res. 92, 617\u2013623 (2001).","journal-title":"Jpn. J. Cancer Res."},{"key":"622_CR9","first-page":"409","volume":"58","author":"T Kawamori","year":"1998","unstructured":"Kawamori, T., Rao, C. V., Seibert, K. & Reddy, B. S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58, 409\u2013412 (1998).","journal-title":"Cancer Res."},{"key":"622_CR10","first-page":"1486","volume":"12","author":"S Lanza-Jacoby","year":"2003","unstructured":"Lanza-Jacoby, S. et al. The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2\/neu mice. Cancer Epidemiol. Biomark. Prev. 12, 1486\u20131491 (2003).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"622_CR11","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa061652","volume":"355","author":"N Arber","year":"2006","unstructured":"Arber, N. et al. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 355, 885\u2013895 (2006).","journal-title":"N. Engl. J. Med."},{"key":"622_CR12","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1056\/NEJMoa061355","volume":"355","author":"MM Bertagnolli","year":"2006","unstructured":"Bertagnolli, M. M. et al. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 355, 873\u2013884 (2006).","journal-title":"N. Engl. J. Med."},{"key":"622_CR13","first-page":"95","volume":"8","author":"ML Leoz","year":"2015","unstructured":"Leoz, M. L., Carballal, S., Moreira, L., Oca\u00f1a, T. & Balaguer, F. The genetic basis of familial adenomatous polyposis and its implications for clinical practice and risk management. Appl. Clin. Genet. 8, 95\u2013107 (2015).","journal-title":"Appl. Clin. Genet."},{"key":"622_CR14","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJM200006293422603","volume":"342","author":"G Steinbach","year":"2000","unstructured":"Steinbach, G. et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342, 1946\u20131952 (2000).","journal-title":"N. Engl. J. Med."},{"key":"622_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2147\/CMAR.S180261","volume":"11","author":"SK Veettil","year":"2019","unstructured":"Veettil, S. K. et al. Efficacy and safety of celecoxib on the incidence of recurrent colorectal adenomas: a systematic review and meta-analysis. Cancer Manag. Res. 11, 561\u2013571 (2019).","journal-title":"Cancer Manag. Res."},{"key":"622_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.15537\/smj.2022.43.1.20210574","volume":"43","author":"TM Mostafa","year":"2022","unstructured":"Mostafa, T. M., Alm El-Din, M. A. & Rashdan, A. R. Celecoxib as an adjuvant to chemotherapy for patients with metastatic colorectal cancer: a randomized controlled clinical study. Saudi Med. J. 43, 37\u201344 (2022).","journal-title":"Saudi Med. J."},{"key":"622_CR17","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1001\/jama.2021.2454","volume":"325","author":"JA Meyerhardt","year":"2021","unstructured":"Meyerhardt, J. A. et al. Effect of celecoxib vs placebo added to standard adjuvant therapy on disease-free survival among patients with stage III colon cancer: the CALGB\/SWOG 80702 (Alliance) Randomized Clinical Trial. JAMA 325, 1277\u20131286 (2021).","journal-title":"JAMA"},{"key":"622_CR18","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.7150\/ijms.44439","volume":"17","author":"J Sheng","year":"2020","unstructured":"Sheng, J. et al. The role of cyclooxygenase-2 in colorectal cancer. Int J. Med Sci. 17, 1095\u20131101 (2020).","journal-title":"Int J. Med Sci."},{"key":"622_CR19","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0092-8674(00)81988-1","volume":"87","author":"M Oshima","year":"1996","unstructured":"Oshima, M. et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87, 803\u2013809 (1996).","journal-title":"Cell"},{"key":"622_CR20","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s10620-013-2917-1","volume":"59","author":"J Song","year":"2014","unstructured":"Song, J., Su, H., Zhou, Y.-Y. & Guo, L.-L. Cyclooxygenase-2 expression is associated with poor overall survival of patients with gastric cancer: a meta-analysis. Dig. Dis. Sci. 59, 436\u2013445 (2014).","journal-title":"Dig. Dis. Sci."},{"key":"622_CR21","doi-asserted-by":"crossref","unstructured":"Kolawole, O. R. & Kashfi, K. NSAIDs and cancer resolution: new paradigms beyond cyclooxygenase. Int. J. Mol. Sci. 23 (2022).","DOI":"10.3390\/ijms23031432"},{"key":"622_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1939-1676.2007.tb02978.x","volume":"21","author":"D Little","year":"2007","unstructured":"Little, D., Jones, S. L. & Blikslager, A. T. Cyclooxygenase (COX) inhibitors and the intestine. J. Vet. Intern Med 21, 367\u2013377 (2007).","journal-title":"J. Vet. Intern Med"},{"key":"622_CR23","doi-asserted-by":"publisher","first-page":"27613","DOI":"10.1074\/jbc.M201119200","volume":"277","author":"S Arico","year":"2002","unstructured":"Arico, S. et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J. Biol. Chem. 277, 27613\u201327621 (2002).","journal-title":"J. Biol. Chem."},{"key":"622_CR24","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1158\/1940-6207.CAPR-10-0030","volume":"3","author":"HN Tinsley","year":"2010","unstructured":"Tinsley, H. N. et al. Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. Cancer Prev. Res. (Philos.) 3, 1303\u20131313 (2010).","journal-title":"Cancer Prev. Res. (Philos.)"},{"key":"622_CR25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/mc.20409","volume":"47","author":"J-W Soh","year":"2008","unstructured":"Soh, J.-W., Kazi, J. U., Li, H., Thompson, W. J. & Weinstein, I. B. Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G. Mol. Carcinog. 47, 519\u2013525 (2008).","journal-title":"Mol. Carcinog."},{"key":"622_CR26","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1002\/anie.200902981","volume":"48","author":"H-J Lee","year":"2009","unstructured":"Lee, H.-J., Wang, N. X., Shi, D.-L. & Zheng, J. J. Sulindac inhibits canonical Wnt signaling by blocking the PDZ domain of the protein Dishevelled. Angew. Chem. Int. Ed. Engl. 48, 6448\u20136452 (2009).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"622_CR27","doi-asserted-by":"crossref","unstructured":"Leiphrakpam, P. D. & Are, C. PI3K\/Akt\/mTOR signaling pathway as a target for colorectal cancer treatment. Int. J. Mol. Sci. 25 (2024).","DOI":"10.3390\/ijms25063178"},{"key":"622_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He, Y. et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct. Target Ther. 6, 425 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"622_CR29","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1158\/0008-5472.CAN-03-2396","volume":"64","author":"SK Kulp","year":"2004","unstructured":"Kulp, S. K. et al. 3-phosphoinositide-dependent protein kinase-1\/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res. 64, 1444\u20131451 (2004).","journal-title":"Cancer Res."},{"key":"622_CR30","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.4049\/jimmunol.173.3.2011","volume":"173","author":"S Shishodia","year":"2004","unstructured":"Shishodia, S., Koul, D. & Aggarwal, B. B. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. J. Immunol. 173, 2011\u20132022 (2004).","journal-title":"J. Immunol."},{"key":"622_CR31","doi-asserted-by":"publisher","first-page":"27307","DOI":"10.1074\/jbc.274.38.27307","volume":"274","author":"Y Yamamoto","year":"1999","unstructured":"Yamamoto, Y., Yin, M. J., Lin, K. M. & Gaynor, R. B. Sulindac inhibits activation of the NF-kappaB pathway. J. Biol. Chem. 274, 27307\u201327314 (1999).","journal-title":"J. Biol. Chem."},{"key":"622_CR32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.4155\/fmc.11.177","volume":"4","author":"LL Winfield","year":"2012","unstructured":"Winfield, L. L. & Payton-Stewart, F. Celecoxib and Bcl-2: emerging possibilities for anticancer drug design. Future Med. Chem. 4, 361\u2013383 (2012).","journal-title":"Future Med. Chem."},{"key":"622_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08108-9","volume":"21","author":"Y Zhuang","year":"2021","unstructured":"Zhuang, Y. et al. Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis. BMC Cancer 21, 380 (2021).","journal-title":"BMC Cancer"},{"key":"622_CR34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/0092-8674(90)90186-I","volume":"61","author":"ER Fearon","year":"1990","unstructured":"Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759\u2013767 (1990).","journal-title":"Cell"},{"key":"622_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/srep14739","volume":"5","author":"J Lu","year":"2015","unstructured":"Lu, J. et al. Network modelling reveals the mechanism underlying colitis-associated colon cancer and identifies novel combinatorial anti-cancer targets. Sci. Rep. 5, 14739 (2015).","journal-title":"Sci. Rep."},{"key":"622_CR36","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.stem.2018.04.020","volume":"22","author":"AM Nicholson","year":"2018","unstructured":"Nicholson, A. M. et al. Fixation and Spread of Somatic Mutations in Adult Human Colonic Epithelium. Cell Stem Cell 22, 909\u2013918.e8 (2018).","journal-title":"Cell Stem Cell"},{"key":"622_CR37","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1053\/j.gastro.2019.08.059","volume":"158","author":"LH Nguyen","year":"2020","unstructured":"Nguyen, L. H., Goel, A. & Chung, D. C. Pathways of colorectal carcinogenesis. Gastroenterology 158, 291\u2013302 (2020).","journal-title":"Gastroenterology"},{"key":"622_CR38","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/bjc.2013.789","volume":"110","author":"B Zhang","year":"2014","unstructured":"Zhang, B. et al. Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway. Br. J. Cancer 110, 946\u2013957 (2014).","journal-title":"Br. J. Cancer"},{"key":"622_CR39","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12876-021-01864-9","volume":"21","author":"T Fang","year":"2021","unstructured":"Fang, T. et al. Prognostic role and clinicopathological features of SMAD4 gene mutation in colorectal cancer: a systematic review and meta-analysis. BMC Gastroenterol. 21, 297 (2021).","journal-title":"BMC Gastroenterol."},{"key":"622_CR40","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1002\/1878-0261.12577","volume":"13","author":"Y Liu","year":"2019","unstructured":"Liu, Y. et al. Klotho-mediated targeting of CCL2 suppresses the induction of colorectal cancer progression by stromal cell senescent microenvironments. Mol. Oncol. 13, 2460\u20132475 (2019).","journal-title":"Mol. Oncol."},{"key":"622_CR41","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.celrep.2015.06.024","volume":"12","author":"E Chun","year":"2015","unstructured":"Chun, E. et al. CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function. Cell Rep. 12, 244\u2013257 (2015).","journal-title":"Cell Rep."},{"key":"622_CR42","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/0959-8049(92)90031-V","volume":"28A","author":"H Lahm","year":"1992","unstructured":"Lahm, H. et al. Growth stimulation of a human colorectal carcinoma cell line by interleukin-1 and -6 and antagonistic effects of transforming growth factor beta 1. Eur. J. Cancer 28A, 1894\u20131899 (1992).","journal-title":"Eur. J. Cancer"},{"key":"622_CR43","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ccr.2009.01.001","volume":"15","author":"S Grivennikov","year":"2009","unstructured":"Grivennikov, S. et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15, 103\u2013113 (2009).","journal-title":"Cancer Cell"},{"key":"622_CR44","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.3748\/wjg.v11.i11.1639","volume":"11","author":"NI Nikiteas","year":"2005","unstructured":"Nikiteas, N. I. et al. Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J. Gastroenterol. 11, 1639\u20131643 (2005).","journal-title":"World J. Gastroenterol."},{"key":"622_CR45","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.3748\/wjg.v23.i10.1780","volume":"23","author":"J Zeng","year":"2017","unstructured":"Zeng, J., Tang, Z.-H., Liu, S. & Guo, S.-S. Clinicopathological significance of overexpression of interleukin-6 in colorectal cancer. World J. Gastroenterol. 23, 1780\u20131786 (2017).","journal-title":"World J. Gastroenterol."},{"key":"622_CR46","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.7150\/ijbs.4614","volume":"8","author":"MJ Waldner","year":"2012","unstructured":"Waldner, M. J., Foersch, S. & Neurath, M. F. Interleukin-6-a key regulator of colorectal cancer development. Int J. Biol. Sci. 8, 1248\u20131253 (2012).","journal-title":"Int J. Biol. Sci."},{"key":"622_CR47","doi-asserted-by":"publisher","first-page":"20315","DOI":"10.1073\/pnas.0810715105","volume":"105","author":"PG Rychahou","year":"2008","unstructured":"Rychahou, P. G. et al. Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc. Natl. Acad. Sci. USA 105, 20315\u201320320 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"622_CR48","doi-asserted-by":"publisher","first-page":"15155","DOI":"10.1073\/pnas.1417549111","volume":"111","author":"M Drosten","year":"2014","unstructured":"Drosten, M. et al. Loss of p53 induces cell proliferation via Ras-independent activation of the Raf\/Mek\/Erk signaling pathway. Proc. Natl. Acad. Sci. USA 111, 15155\u201315160 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"622_CR49","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.celrep.2014.07.019","volume":"8","author":"A-M Baker","year":"2014","unstructured":"Baker, A.-M. et al. Quantification of crypt and stem cell evolution in the normal and neoplastic human colon. Cell Rep. 8, 940\u2013947 (2014).","journal-title":"Cell Rep."},{"key":"622_CR50","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/nature10708","volume":"482","author":"M Castets","year":"2011","unstructured":"Castets, M. et al. DCC constrains tumour progression via its dependence receptor activity. Nature 482, 534\u2013537 (2011).","journal-title":"Nature"},{"key":"622_CR51","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1471-213X-11-41","volume":"11","author":"A VanZomeren-Dohm","year":"2011","unstructured":"VanZomeren-Dohm, A., Sarro, J., Flannery, E. & Duman-Scheel, M. The Drosophila Netrin receptor frazzled\/DCC functions as an invasive tumor suppressor. BMC Dev. Biol. 11, 41 (2011).","journal-title":"BMC Dev. Biol."},{"key":"622_CR52","doi-asserted-by":"publisher","first-page":"ii37","DOI":"10.1093\/bioinformatics\/btae384","volume":"40","author":"S Lakbir","year":"2024","unstructured":"Lakbir, S. et al. CIBRA identifies genomic alterations with a system-wide impact on tumor biology. Bioinformatics 40, ii37\u2013ii44 (2024).","journal-title":"Bioinformatics"},{"key":"622_CR53","doi-asserted-by":"publisher","first-page":"314","DOI":"10.7150\/jca.13332","volume":"7","author":"X Chen","year":"2016","unstructured":"Chen, X., Duan, N., Zhang, C. & Zhang, W. Survivin and tumorigenesis: molecular mechanisms and therapeutic strategies. J. Cancer 7, 314\u2013323 (2016).","journal-title":"J. Cancer"},{"key":"622_CR54","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1091\/mbc.e03-07-0512","volume":"15","author":"Z Song","year":"2004","unstructured":"Song, Z. et al. A single amino acid change (Asp 53 -> Ala53) converts Survivin from anti-apoptotic to pro-apoptotic. Mol. Biol. Cell 15, 1287\u20131296 (2004).","journal-title":"Mol. Biol. Cell"},{"key":"622_CR55","doi-asserted-by":"crossref","unstructured":"Wheatley, S. P. & Altieri, D. C. Survivin at a glance. J. Cell Sci. 132 (2019).","DOI":"10.1242\/jcs.223826"},{"key":"622_CR56","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1158\/1078-0432.CCR-04-1752","volume":"12","author":"T Gritsko","year":"2006","unstructured":"Gritsko, T. et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res. 12, 11\u201319 (2006).","journal-title":"Clin. Cancer Res."},{"key":"622_CR57","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1074\/jbc.M106643200","volume":"277","author":"WH Hoffman","year":"2002","unstructured":"Hoffman, W. H., Biade, S., Zilfou, J. T., Chen, J. & Murphy, M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem. 277, 3247\u20133257 (2002).","journal-title":"J. Biol. Chem."},{"key":"622_CR58","doi-asserted-by":"publisher","first-page":"111128","DOI":"10.1016\/j.biopha.2020.111128","volume":"134","author":"WS Ahmed","year":"2021","unstructured":"Ahmed, W. S., Geethakumari, A. M. & Biswas, K. H. Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors. Biomed. Pharmacother. 134, 111128 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"622_CR59","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1038\/onc.2010.91","volume":"29","author":"I-K Kwon","year":"2010","unstructured":"Kwon, I.-K. et al. PKG inhibits TCF signaling in colon cancer cells by blocking beta-catenin expression and activating FOXO4. Oncogene 29, 3423\u20133434 (2010).","journal-title":"Oncogene"},{"key":"622_CR60","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.cell.2012.05.002","volume":"149","author":"VSW Li","year":"2012","unstructured":"Li, V. S. W. et al. Wnt signaling through inhibition of \u03b2-catenin degradation in an intact Axin1 complex. Cell 149, 1245\u20131256 (2012).","journal-title":"Cell"},{"key":"622_CR61","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.4161\/cc.4.11.2129","volume":"4","author":"SY Fuchs","year":"2005","unstructured":"Fuchs, S. Y., Ougolkov, A. V., Spiegelman, V. S. & Minamoto, T. Oncogenic beta-catenin signaling networks in colorectal cancer. Cell Cycle 4, 1522\u20131539 (2005).","journal-title":"Cell Cycle"},{"key":"622_CR62","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000066755","volume":"66","author":"FT Kolligs","year":"2002","unstructured":"Kolligs, F. T., Bommer, G. & G\u00f6ke, B. Wnt\/beta-catenin\/tcf signaling: a critical pathway in gastrointestinal tumorigenesis. Digestion 66, 131\u2013144 (2002).","journal-title":"Digestion"},{"key":"622_CR63","first-page":"728","volume":"63","author":"Y Araki","year":"2003","unstructured":"Araki, Y. et al. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res. 63, 728\u2013734 (2003).","journal-title":"Cancer Res."},{"key":"622_CR64","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.1073\/pnas.96.10.5522","volume":"96","author":"M Shtutman","year":"1999","unstructured":"Shtutman, M. et al. The cyclin D1 gene is a target of the beta-catenin\/LEF-1 pathway. Proc. Natl. Acad. Sci. USA 96, 5522\u20135527 (1999).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"622_CR65","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/nrc1504","volume":"4","author":"H Arakawa","year":"2004","unstructured":"Arakawa, H. Netrin-1 and its receptors in tumorigenesis. Nat. Rev. Cancer 4, 978\u2013987 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"622_CR66","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/cdd.2015.50","volume":"22","author":"ARD Delbridge","year":"2015","unstructured":"Delbridge, A. R. D. & Strasser, A. The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ. 22, 1071\u20131080 (2015).","journal-title":"Cell Death Differ."},{"key":"622_CR67","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1093\/bioinformatics\/btw747","volume":"33","author":"I Irurzun-Arana","year":"2017","unstructured":"Irurzun-Arana, I., Pastor, J. M., Troc\u00f3niz, I. F. & G\u00f3mez-Mantilla, J. D. Advanced Boolean modeling of biological networks applied to systems pharmacology. Bioinformatics 33, 1040\u20131048 (2017).","journal-title":"Bioinformatics"}],"container-title":["npj Systems Biology and Applications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41540-025-00622-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-025-00622-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-025-00622-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T11:04:54Z","timestamp":1775732694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41540-025-00622-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["622"],"URL":"https:\/\/doi.org\/10.1038\/s41540-025-00622-x","relation":{},"ISSN":["2056-7189"],"issn-type":[{"value":"2056-7189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jan Snoeys is employed by and holds stock in Johnson & Johnson. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}